In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Prevenar 13 is a vaccine, which is a type of medicine ... Prevenar 13 is a mixture of the outer sugar coating (polysaccharide) from 13 different strains or serotypes of bacteria called ...

followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses to Prevnar 20 in patients aged 18 to 59 years were also assessed, along with the safety profile of ...

Conventional conjugate vaccines use covalent bonding to join the polysaccharide and protein antigens, which affects the way both are presented to the immune system. The phase 2 trial involved more ...

The O-specific polysaccharide of Klebsiella pneumoniae in patients with bloodstream infections is immunogenic, and its closely related subtypes are cross-reactive.

In both studies, patients received either meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92%, respectively ...

2). However, as with polysaccharide vaccines in general, it has important limitations, including lack of induction of immunological memory, relatively short duration of protection and lack of ...

The development by Wyeth of the vaccine Prevnar, as well as being a commercial success, was also a technological triumph. Conceptually, the approach was not new; pneumococcal polysaccharide ...